This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Three 'Male Menopause' Stocks With Muscle

BOSTON -- Women aren't the only ones suffering through "hormonal difficulties" as they get older.

It happens to guys, too. As men get older, testosterone production declines, leading to a host of symptoms that include reduced sex drive, erectile dysfunction, loss of muscle and energy, even depression.

The medical term for this condition is hypogonadism, but it can also be known as male menopause. (Or how about "manopause?") Researchers believe that 19 million men in the U.S. suffer from testosterone deficiency, but right now, only 10% of them are diagnosed and treated, according to a report compiled by ThinkEquity Partners, which held a conference on reproductive health (including male sexual health issues) last week in New York.

Still, this relatively small patient population accounts for about $500 million to $600 million in annual sales of testosterone replacement products -- gels, patches and injectables. And as U.S. males get older and more of them seek out diagnosis and treatment, this testosterone replacement market is going to grow strongly.

With that in mind, here are three "male menopause" stock plays to consider:

Indevus Pharmaceuticals (IDEV):

The current testosterone replacement market is dominated by quick-drying gels, which men must rub on their bodies (usually a shoulder) daily. The gels become part of a daily routine, but still, the hassle of applying a gel to the body every day, waiting for it to dry before dressing, etc., can be a chore.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs